# OnCo record paper-combi-ad-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-combi-ad-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-combi-ad-nejm-2017" ;
  schema:name "COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma"@en ;
  schema:description "A year of dabrafenib plus trametinib after surgery for stage III BRAF-mutant melanoma cut the risk of relapse by more than half, giving patients with BRAF mutations a targeted alternative to adjuvant immunotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-combi-ad-nejm-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1708539>, <https://pubmed.ncbi.nlm.nih.gov/28891408/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1708539> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Long GV, Hauschild A, Santinami M, et al." ;
  onco:cancers <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/> ;
  onco:trials <https://onco.cc/trials/combi-ad/> ;
  onco:journals <https://onco.cc/journals/nejm/> .